DNASE1L2: A Potential Drug Target and Biomarker for ALS (G1775)

Target Name: DNASE1L2

NCBI ID: G1775

DNASE1L2

DNASE1L2: A Potential Drug Target and Biomarker for ALS

Amyloid-associated protein (AAP) is a large transmembrane protein that is involved in the formation of amyloid plaques, which are a hallmark of Alzheimer's disease (AD). The protein is composed of four isoforms, including DNASE1L2, which has been identified as a potential drug target and biomarker for ALS (Amyloid-associated protein-rich neurodegeneration). This article will discuss the biology of DNASE1L2, its potential as a drug target, and its potential as a biomarker for ALS.

Biography of DNASE1L2

DNASE1L2 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a member of the DNase family, which includes several isoforms, including DNASE1, DNASE2, DNASE3, and DNase4. DNase1L2 is characterized by its unique N-terminus and C-terminus, which contain a nucleotide-binding oligomerization domain (NBO), a protein-coding domain, and a C-terminus that is involved in the formation of covalent bonds with other proteins.

DNase1L2 functions as a enzyme that can remove the amyloid-associated protein (AAP) from amyloid plaques. AAP is a key protein that is involved in the formation of amyloid plaques, which are a hallmark of AD. The presence of AAP in amyloid plaques is thought to contribute to the neurotoxicity of these plaques, which is a major risk factor for the development of AD.

DNase1L2 has been shown to have neuroprotective properties in various models of ALS, including in animal models of ALS. For example, overexpression of DNase1L2 has been shown to protect against neurotoxicity in ALS mouse models, including a reduction in the expression of AAP and tau, which are hallmark proteins of AD.

Potential as a Drug Target

The identification of DNase1L2 as a potential drug target is based on its unique functions as an enzyme that can remove AAP from amyloid plaques. AAP is a key protein that is involved in the formation of amyloid plaques, which are a hallmark of AD. The presence of AAP in amyloid plaques is thought to contribute to the neurotoxicity of these plaques, which is a major risk factor for the development of AD.

DNase1L2 has been shown to have neuroprotective properties in various models of ALS, including in animal models of ALS. For example, overexpression of DNase1L2 has been shown to protect against neurotoxicity in ALS mouse models, including a reduction in the expression of AAP and tau, which are hallmark proteins of AD.

In addition, DNase1L2 has been shown to have a low expression level in human ALS brain, which suggests that it may be a potential target for small molecule inhibitors.

Potential as a Biomarker

DNase1L2 has also been shown to have potential as a biomarker for ALS. The presence of AAP in amyloid plaques is a hallmark of AD, and the levels of AAP in these plaques are thought to contribute to the neurotoxicity of these plaques.

DNase1L2 has been shown to have neuroprotective properties in various models of ALS, including in animal models of ALS. For example, overexpression of DNase1L2 has been shown to protect against neurotoxicity in ALS mouse models, including a reduction in the expression of AAP and tau, which are hallmark proteins of AD.

In addition, DNase1L2 has been shown to have a low expression level in human ALS brain, which suggests that it may be a potential target for small molecule inhibitors. Furthermore, DNase1L2 has been shown to have a unique expression pattern in ALS brain, which may be a potential biomarker for this disease.

Conclusion

In conclusion, DNase1L2 is a protein that has been identified as a potential drug target and biomarker for ALS. Its unique functions as an enzyme that can remove AAP from amyloid plaques and its neuroprotective properties in various models of ALS make it a promising target for small molecule inhibitors. Further research is needed to confirm its potential as a drug and to develop biomarkers for ALS.

Protein Name: Deoxyribonuclease 1 Like 2

Functions: Divalent cation-dependent acid DNA endonuclease involved in the breakdown of the nucleus during corneocyte formation of epidermal keratinocytes. May play an immune role by eliminating harmful DNA released into the extracellular environment by damaged epidermal cells

The "DNASE1L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNASE1L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets